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On May 26–28, 2009, an international symposium on IgA
nephropathy was convened in Stresa, Italy, as a Satellite
Symposium of the World Congress of Nephrology held in
Milan. This meeting was attended by a large number of
scientists and clinicians working in the field of IgA
nephropathy. The oral and poster presentations (over 70)
ranged from very fundamental structural biology to clinical
management. This article attempts to summarize the main
findings of the meeting and to put forth some new
perspectives and hypotheses regarding human IgA
nephropathy on the 41st anniversary of its original
description by Berger and Hinglais in 1968.
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The remarkable feature of the 12th International Gathering of
the Acolytes and Apostles of IgA Nephropathy in Stresa, Italy,
by the glimmering shores of Lago Maggiore (see Figure 1),
was the coalescence of thought and discussion on a limited
number of themes. Unlike prior meetings, one gained the
distinct impression that science was honing in on such
matters as defining pathogenesis, accurate prediction of
outcomes, systematizing the approach to morphology of the
disease, and enhancing diagnosis and treatment in a much
more focused manner than heretofore in evidence. This is not
to say that the topics discussed were not diverse, but they
seemed to mostly play into a web of connectivity.
Not surprisingly, new data generated novel hypotheses,
testable by future studies, and undoubtedly potential subjects
for future meetings.
The comments that follow are not intended to be a
comprehensive summary of the meeting but rather reflect
the perspectives of a spectator (rather than a combatant)
and of the two organizers in this dynamic arena of
clinical and basic science, dealing with one of the most
important and certainly most common of the primary
glomerular diseases.
EPIDEMIOLOGY THEME
There is no doubt that IgA nephropathy is an extremely
common ‘disease.’1 In reality, it is a clinicopathological
phenotype, underlying which may be a remarkable degree
of as-yet undiscovered heterogeneity of both etiology and
pathogenesis. It seems quite clear that apparently ‘normal’
subjects (such as healthy living donors for kidney transplant-
ation) do not uncommonly (4–16%; averaging about 70,000
per million population) have hidden or ‘lanthanic’ mesangial
deposits of IgA (usually without co-deposition of IgG or
C3).2 It can be debated whether this is an ‘innocent’ finding
or whether these subjects represent a state of ‘pre-disease’
awaiting another event (a second ‘hit’) to bring the disease to
full clinical and recognizable expression. The ratio of subjects
with ‘lanthanic’ glomerular deposits of IgA to those with
clinically overt disease can be estimated at about 80 to 1;
hence, conversion from a hypothetical ‘pre-disease’ to an
overt disease by a postulated ‘second hit’ is quite an
uncommon event. It is of interest that IgA nephropathy in
the ddY mouse, which has considerable resemblance to the
human disease, presents with a similar variability, including
early and late-onset overt disease, and even covert disease
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detected only by renal biopsy.3 As will be discussed below,
we do not yet know whether these ‘lanthanic’ deposits share
the biochemical characteristics found in overt IgA nephro-
pathy, namely a predominance of IgA1 isotype missing crucial
galactose and sialic-acid-containing residues at some of the
5–9 glycan side chains in the hinge region.4 If the ‘lanthanic’
deposits of IgA are the same as those found in ‘disease,’
then a re-assessment of the genetic association studies that
used only overtly diseased subjects will be required. The
alteration in galactosylation (and sialylation) of the glycans
of IgA1 would be predicted to alter the three-dimensional
structure of the molecule (which normally is a highly planar
T-shaped structure) and possibly affect its affinity and bind-
ing to intrinsic mesangial glycoproteins (such as fibronectin,
laminin, collagens)5 and plasma proteins (such as mannose-
binding lectin and properdin)6 just as it alters the binding
to plant and animal lectins by exposure of normal cryptic
ligands (such as GalNac) and by self-aggregation. Whether
these biophysical phenomena relate to pathogenesis of the
human disease will be discussed below.
GENETICS AND PATHOGENESIS THEME
It still remains unclear whether the aberrant glycosylation of IgA
is transmitted in the germ line or whether it is acquired in
sporadic IgA nephropathy, but similar defects in the main
galactosyltransferase and sialyltransferase enzymes have been
described in both familial and sporadic cases of IgA nephro-
pathy, and elevated serum levels of galactose-deficient IgA are
found in apparently healthy first-degree relatives of patients with
overt IgA nephropathy but not in ‘live-in’ non-blood relatives
(spouses).7 Similar observations were confirmed during the
satellite meeting in Stresa in Japanese and Chinese patients.
These data strongly suggest a hereditable component to
‘sporadic’ IgA nephropathy, although at the same time they
indicate the participation of additional factors, besides the
presence of underglycosylated IgA1 in the circulation, to produce
clinically overt renal disease. Conflicting data for C1GALT1, the
gene encoding the key enzyme b1,3-galactosyltransferase, have
been reported. Whereas in a Chinese population, IgA three
single-nucleotide polymorphisms of C1GALT1 have been
reported in association with IgA nephropathy,8 this was not
confirmed in a French population reported by Berthoux in the
meeting. In both Caucasian and Asian patients, no difference has
been detected for C1GALT1C1 encoding the b1,3-galactosyl-
transferase chaperone protein, Cosmc.8,9
The sporadic disease might be a consequence of a limited
number of mutations in a single (or a few) common gene (s)
or due to mutations in many genes, interacting with each
other to produce the phenotype. This is a crucial issue that
will require large-scale investigations including genome-
wide association studies. Among the genetic factors possibly
influencing the development of severity of IgA nephropathy,
newly reported results indicated a possible role of trans-
forming growth factor-b1 gene single-nucleotide polymorph-
isms or adhesion molecule (glycoprotein Ia or members
of immunoglobulin superfamily) polymorphisms selected
from multiple atherosclerotic disease-related genes. A genetic
component in the regulation of production or expression of
soluble myeloid IgA receptor (sCD89), which may relate to
splicing mechanisms, has been also suggested.
The presence in circulation of aberrantly glycosylated
IgA1 in patients with IgA nephropathy10–12 was amply
confirmed. Individual O-galactosylation patterns of serum
IgA1 were reported by the Smith and Feehally group
(Leicester, UK) to remain constant over long periods of
time. These were also loosely associated with the severity of
renal disease, but the overlap between different groups of
progressors or non-progressors suggested that altered IgA1
O-glycosylation alone is insufficient to trigger progression.
In agreement with this report, a collaborative study among
Italian and US researchers, presented by the group of Camilla
and Coppo (Torino, Italy), showed that the concomitant
presence in patient sera of aberrantly glycosylated IgA1
and signs of oxidative stress, advanced oxidation protein
products, and free thiol groups of serum albumin increase
the predictive value for disease progression.
The elegant and ground-breaking studies of Suzuki,
Novak, Mestecky and colleagues (Birmingham, AL, USA)
using immortalized B cells from subjects with IgA nephro-
pathy and normal controls13 have shown that the aberrant
galactosylation in patients is nonrandomly distributed among
the glycan residues (only three specific sites are affected) and
that premature sialylation of the GalNac residues, due to the
heightened activity of a2,6-sialyl transferase, may interfere
with galactosylation of GalNac. Cryptic epitopes related to
GalNac, in a manner yet to be determined, lead to the
production of autoantibodies to GalNac14 that show a
remarkable degree of restricted heterogeneity of the epitope
binding sites. Taken together, these findings suggest that
‘molecular mimicry’ from environmental agents (such as
ubiquitous bacterial and viral envelope proteins) may be
involved in the autoantibody response to the cryptic,
neo-antigenic GalNac sites on the aberrant IgA1. They do
not yet explain why IgG is not uniformly found, co-deposited
with IgA, in the mesangial deposits of IgA nephropathy.
Furthermore, no evidence of intramolecular or inter-
molecular epitope spreading of autoantibody reactivity, so
common in many other chronic autoimmune diseases, has
Figure 1 | Stresa, Lago Maggiore, Italy. Venue for the World
Congress of Nephrology Satellite Symposium on IgA Nephropathy,
May 2009.
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yet been observed in IgA nephropathy, and a search for this
phenomenon is warranted.
Nevertheless, IgA nephropathy has stigmata of a true
autoimmune disease, in which both autoantigen and
autoantibody are derived from the same general class of
lymphoid cells (CD-19þ B cells) of mucosal (tonsils, gut)
and bone marrow origin.15 Integration of these seminal
findings into a composite picture of pathogenesis of
glomerular injury, however, remains incomplete. The domi-
nant view, largely based on indirect observations, is that
autoantigen (polymeric galactose deficient IgA1) and auto-
antibody (oligoclonal IgG1 and possibly IgA) join to form
circulating immune complexes that subsequently deposit in
the glomerular mesangium, perhaps by interaction with IgA
receptors (such as the transferrin receptor, CD71) located on
the surface of mesangial cells.16 The group of Houda and
Monteiro (Paris, France) reported that IgA from IgA
nephropathy patients induces mesangial CD71 expression
and cell activation in immunodeficient mice. CD89 may also
have a pathogenetic role, as mice expressing human IgA1 and
human CD89 develop IgA nephropathy.
The unique chemical composition and three-dimensional
structure of the deposited immune complexes provoke
a cascade of mediators (for example, mannose-binding
lectin and properdin-dependent alternative complement
pathway activation, cytokine and chemokines elaboration)
leading to overt glomerular injury. Updates on the multiple
biological effects of aberrantly glycosylated IgA related to
pathogenesis and progression of IgA nephropathy were
provided by Lai (Hong Kong) and Daha (Leiden, The
Netherlands), focusing on complement activation17 and
glomerular-podocytic and glomerular-tubular cross-talk
leading to the development of proteinuria.18 Alternative
pathogenetic mechanisms are also hypothetically possible;
for example, the multimeric, aberrantly galactosylated IgA
may acquire properties leading to its deposition in the
mesangium (initially without antibody). These deposits
could then serve as a ‘planted’ autochthonous antigen
for subsequent interaction with autoantibodies from the
circulation forming immune complexes in situ. In this
scenario, the circulating immune complexes would be
nonessential epiphenomena, and urinary immune complexes
could be those ‘shed’ from the in situ deposits. In addition,
the glomerular deposits of aberrantly galactosylated IgA
(again in the absence of antibody) could locally activate
mediators, such as mannose-binding lectin and properdin,
directly because of their unique composition and structural
configuration in tissue. Urinary C5b-9 was reported at the
meeting as a possible prognostic factor in IgA nephropathy.
A role for T-cell conditioning, including Th2 subset preva-
lence, Toll-like receptor activation on circulating lympho-
monocytes, and altered Treg and Th-17 subset regulation,
was also reported. These postulated mechanisms or cofactors
are not mutually exclusive, and additional studies will be
required to confirm or deny their participation in the
pathogenesis of human IgA nephropathy.
DIAGNOSIS AND PROGNOSIS THEME
Importantly, these fundamental advances in pathogenesis
have opened up new avenues for the noninvasive diagnosis of
IgA nephropathy (for example, anti-GalNac autoantibody
testing, and quantification of serum under-galactosylated
IgA1) and will undoubtedly provide much new data bearing
on the assessment of clinical activity of disease, its prognosis,
and response to treatment, and perhaps shed new light on the
well-known propensity of IgA nephropathy to recur in the
transplanted kidney (see below). However, it is not likely that
these advances will replace renal biopsy as the time-honored
approach to evaluating patients suspected of having IgA
nephropathy, at least over the short term.
The ability to predict the long-term outcome of IgA
nephropathy has steadily improved over the past few decades
and several new approaches were described at this meeting.
Most notably, the first report of the ground-breaking Oxford
classification of the pathology of IgA nephropathy19,20 was
presented and discussed. This international collaborative
effort will be producing new data on the relationship of
pathology to outcome for several years to come. It provides a
new common language and a simple, user-friendly and
reproducible systematic approach to categorizing glomerular
and tubulo-interstitial lesions in IgA nephropathy having a
likely bearing on progression. Although retrospective in
design and requiring future prospective validation, the
Oxford collaboration defined and scored four pathological
parameters having an influence on outcome (independent of
clinical information); including mesangial (M) and endoca-
pillary (E) proliferation (hypercellularity), glomerulosclerosis
(S), and tubular atrophy and interstitial fibrosis (T). These
parameters were largely defined in adults and may have to be
refined for children. The scheme will likely become known as
the OXFORD-MEST scoring system. Necrotizing and cres-
centic lesions were not evaluated because of their rarity in the
cases reviewed, and immunofluorescence and electron
microscopy were not included in the enumerated parameters
largely due to pragmatic considerations. It is not yet known
whether these missing data points will prove to be a serious
weakness in the classification schema. Future studies will be
needed to confirm whether the OXFORD-MEST system
represents an improvement over existing pathology grading
systems, of which the most widely used has been that of Haas.
The fact that the OXFORD-MEST system is based solely on
light microscopy may be both an advantage and a
disadvantage. It confers an advantage of applicability across
a wide range of renal pathology centers, but it does not
incorporate some of the newer pathological parameters
shown to have independent prognostic import, such as
phenotyping of the T-cells subsets21 and enumerating the
fibroblast-specific protein-1-positive cells in the interstitial
infiltrate.22 Transcriptomic analysis of microdissected glo-
meruli and tubules may also soon provide a new dimension
of prognostication based on renal tissue examination, but
proof of the utility of this approach will likely be slow to
emerge. Time will tell if the new OXFORD-MEST system will
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finally settle the long-standing and controversial issue of
whether renal pathology makes an independent contribution,
over and above simple clinical parameters, to the estimation
of long-term prognosis in IgA nephropathy. This is a crucial
issue having bearing on the design and execution of future
controlled clinical trials of therapy, which depend on
reasonably accurate appraisal of event rates (decline in
glomerular filtration rate, doubling of serum creatinine or
end-stage renal disease (ESRD)) in relatively homogeneous
groups of patients in order to plan adequately powered but
economically viable trials with clinically relevant end points.
Perhaps future analysis of genome-wide association and
single-nucleotide polymorphism studies may shed additional
light on prognosis in IgA nephropathy, but such studies have
not yet provided any useful data for individual prognostica-
tion. On the other hand, sophisticated studies of the
biochemical composition of urine, including individual
cytokines and growth factors and proteomic analysis,23 are
under evaluation in refining our current faulty prognostic
capabilities in IgA nephropathy.
THERAPY AND TRANSPLANTATION THEME
Progress in treatment of IgA nephropathy has been slow (but
relentless), largely because of the necessity for long-term
observation to accrue sufficient primary end point events or
to evaluate a biologically relevant change in renal function for
statistical evaluation of cogent effects. Many studies have had
to rely on surrogate end points, such as a decline in the
magnitude of proteinuria. Nevertheless, a strong consensus
has emerged that inhibition of the renin–angiotensin–aldos-
terone system (RAAS) is the desired initial approach to
treatment of selected patients having features indicative of a
poor long-term prognosis and a reasonably high risk of
developing ESRD.24,25 Controversy still exits as how to best
achieve the goal of ‘complete’ inhibition of RAAS. Standard
(regulatory authority approved) doses of an angiotensin-
converting enzyme inhibitor (ACEi) or an angiotensin
receptor blocker (ARB) fail to achieve a lowering of
proteinuria in about 30–40% of patients. Supramaximal
doses of either an ACEi or an ARB (often with salt restriction
and/or diuretics) can in some circumstances show an
enhanced effect on reducing proteinuria, but the long-term
effects of this strategy on the development of ESRD are not
yet fully understood. Dual therapy (using standard but
maximal doses) of both an ACEi and an ARB (or an ACEi or
ARB combined with a direct renin inhibitor or an
aldosterone antagonist) may ultimately prove to be the
treatment of choice but the limited trial data are not yet
conclusive on this point.26,27 Safety issues (hyperkalemia,
renal artery stenosis) remain an unresolved concern. Slow
escalation of ACEi or ARB monotherapy (with modest salt
restriction and/or diuretics) dosing using both blood pressure
control (o125/80mmHg) and a substantial decline in
proteinuria (to o500mg/dl is preferable than 450%
reduction from baseline) as the goal of therapy seems to be
the best current evidence-based approach. For those who fail
to reach these goals, the addition of glucocorticoids (cyclical
IV and oral) therapy (as in the Pozzi regimen) may provide
additional protection from ESRD, but long-term failure is
still seen (10-year renal survival of treated patients was
97%).28 Perhaps the initial and simultaneous combination of
both RAAS inhibition and steroid therapy will prove to be
superior to either therapy given alone, but more trials are
needed to show this conclusively. German multicenter studies
(Eitner and Keller) are ongoing and their design was
presented at the meeting.29 The addition of cytotoxic
immunosuppressive agents (cyclophosphamide and
azathioprine sequential therapy, as reported by Ballardie
and Roberts)30 can be of benefit in progressive cases, and
even more intensive regimens (IV methylprednisolone,
cyclophosphamide, and plasma exchange) may be required
for those uncommon patients with a rapidly progressive
course associated with extensive crescents. Adjunctive use of
fish oil therapy may be effective and is very safe when added
to RAAS inhibition or to glucocorticoid therapy, but many
patients fail to comply because of the disagreeable odiferous
side effects. A number of proposed treatment regimens are
either demonstrably ineffective or require much more
investigation to be included as evidence-based therapy for
IgA nephropathy. These include glucocorticoids combined
with azathioprine: Pozzi reported no additional benefit
obtained in a multicenter study, although Stangou in a
single-center study found some greater effects in reducing the
degree of proteinuria, and preserving renal function. The role
of tonsillectomy in the management of IgA nephropathy31
remains inconclusive because of the total lack of any
randomized, prospective clinical trials with sufficiently long
follow-up to assess the effects on progressive renal disease.
Observational studies do support the beneficial effects of
tonsillectomy on clinical features, such as hematuria and
proteinuria, particularly in children and when used in
combination with ‘pulses’ of IV methylprednisolone.32 Some
reports at the meeting focused on a possible benefit of
adjunctive tonsillectomy to steroid pulse therapy on the
clinical features of IgA nephropathy diagnosed as having a
poor prognosis.
The optimistic side of the discussion indicates that we
now have many options for treatment of IgA nephropathy
that are evidence-based. It can be envisioned that these
advances have somewhat reduced the overall risk for
progression of IgA nephropathy to ESRD, but more needs
to be accomplished in this arena. Hopefully, the astounding
advances in the understanding of pathogenesis of IgA
nephropathy will lead to more ‘disease-directed’ forms of
treatment rather than the empiric regimens in use today.
Kidney transplantation is the ultimate ‘treatment’ for IgA
nephropathy when all regimens fail to halt progressive
disease. Unfortunately, even transplantation is not curative,
as 30–50% or even more of the subjects so treated will
develop a ‘recurrence’ of the disease in the allograft (or
isograft) if followed for X5 years.33 But fortunately these
recurrences have only a minor impact on overall graft and
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patient survival, at least for the first decade after transplanta-
tion.34 To be sure, some patients with recurrence do
prematurely lose grafts from recurrence, but these are largely
those with a very aggressive original disease (often associated
with extensive crescentic glomerulonephritis or severe
Henoch-Scho¨nlein purpura).
Predicting the risk of recurrence is difficult and impre-
cise.35 Several factors seems to be useful: (1) prior recurrence
of disease and loss of graft from recurrence; (2) rapidly
progressive course of the original disease accompanied by
extensive crescents; (3) the use of zero-mismatched donors or
living related donors. Two other postulated factors are
controversial as they emanate from single-center studies
and have not yet been independently confirmed; (4) the lack
of treatment with an anti-lymphocyte or anti-thymocyte
induction immunosuppressive regime regimen; and (5) the
presence of IgA deposits in the transplanted kidney by ‘zero-
hour’ transplant renal biopsies. In addition, the special risk of
recurrence afforded by use of well-matched kidneys has not
been uniformly observed and the long-term outcome of
transplantation in IgA nephropathy is not different than
other glomerular diseases after taking into account the donor
source. Thus, the prospect of a recurrence should not
dissuade clinicians from applying the benefits of renal
transplantation to patients with IgA nephropathy and
ESRD. With the possible exception of the use of anti-
lymphocyte induction regimens, the post-transplant main-
tenance immunosuppressive treatment protocol has little
or no effect on the risk of recurrence. The finding that
the presence of ‘lanthanic’ IgA deposits in the ‘normal’
donor kidney (detected by ‘zero-hour’ renal biopsies)
may have important relevance for pathogenesis of the
recurrent disease. It should be presumed that circulating
autoantibody to GalNac (see above) in some subjects with
IgA nephropathy could react with the ‘planted’ and
‘lanthanic’ IgA deposits (if they are indeed deficient in
galactose residues thus exposing the neo-GalNac epitopes)
and promote recurrence. Whether this immunopathological
recurrence would rise to the level of clinical detection would
depend on the activation of accessory factors, such as
complement and cytokines. This hypothetical sequence is not
incompatible with a role for deposition of IgA containing
immune complexes from the circulation as a causative factor
in recurrent disease as well. This seems to be a rich minefield
for future discovery.
CONCLUSION
In sum, like its predecessors, the Stresa gathering provided
much new information to be digested and assimilated into
the framework of IgA nephropathy. It also consolidated,
confirmed, and codified an ever-expanding database of
information about an enigmatic but extremely common
disease. Combining the new with the old generates an
increasingly complete picture of a disease phenotype and its
underlying heterogeneity. New hypotheses, readily testable by
current sophisticated methodology, were generated.
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